Movatterモバイル変換

[0]ホーム

Пређи на садржај

VIPR1

Уреди везе

С Википедије, слободне енциклопедије

Receptor vazoaktivnog intestinalnog peptida 1

Prikaz baziran na PDB1OF2

Dostupne strukture

1OF2,1OGT,3B3I

Identifikatori

Simboli

VIPR1; HVR1; II; PACAP-R-2; PACAP-R2; RDC1; V1RG; VAPC1; VIP-R-1; VIPR; VIRG; VPAC1; VPAC1R; VPCAP1R

Vanjski ID

OMIM: 192321MGI: 109272HomoloGene: 3399IUPHAR:VPAC₁GeneCards:VIPR1 Gene

Ontologija gena
Molekularna funkcija	•aktivnost vazoaktivnog intestinalnog polipeptidnog receptora
Celularna komponenta	•jedro •nukleolus •citoplazma •ćelijska membrana
Biološki proces	•mišićne kontrakcije •imunski sistem •signalni put G-protein spregnutog receptora

Pregled RNK izražavanja

podaci

Ortolozi

Vrsta

Čovek

Miš

RefSeq (mRNA)

RefSeq (protein)

Lokacija (UCSC)

Chr 3:
42.53 - 42.58 Mb

Chr 9:
121.55 - 121.58 Mb

PubMed pretraga

[1]

[2]

Receptor vazoaktivnog intestinalnog peptida 1 (VPAC₁) jeprotein koji je kod ljudi kodiranVIPR1genom.^[1] VPAC₁ je izražen u mozgu (cerebralni korteks,hiokampus,amigdala),plućima,prostati, perifernim krvnimleukocitima,jetri,tankim crevima,srcu,slezini,posteljici,bubrezima,grudnoj žlezdi itestisima.^[2]^[3]^[4]

Function

[уреди |уреди извор]

VPAC₁ je receptor zaneuropeptid vazoaktivni intestinalni peptid (VIP). Taj peptid učestvuje u relaksacijiglatkih mišića, egzokrinoj i endokrinojsekreciji, i protoku vode i jona uplućima i intestinalnomepitelnom tkivu. Njegovo dejstvo se ispoljava putem integralnihmembranskih receptora asociranih saG proteinima koji aktivirajuadenilat ciklazu.^[1]

VIP deluje naautokrini način putem VPAC₁1 da inhibira proliferacijumegakariocita i indukuje formiranjeprotrombocita.^[5]^[6]

Reference

[уреди |уреди извор]

^^а ^б„Entrez Gene: VIPR1 vasoactive intestinal peptide receptor 1”.
^Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S (1992). „Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.”.Neuron.8 (4): 811—819.PMID 1314625.doi:10.1016/0896-6273(92)90101-I.
^Usdin TB, Bonner TI, Mezey E (1994). „Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions.”.Endocrinology.135 (6): 2662—2680.PMID 7988457.doi:10.1210/en.135.6.2662.
^Sreedharan SP, Huang JX, Cheung MC, Goetzl EJ (1995).„Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene”.Proc Natl Acad Sci USA.92 (7): 2939—2943.PMC 42334 .PMID 7708752.doi:10.1073/pnas.92.7.2939.
^Nam, C.; Case, A. J.; Hostager, B. S.; O’Dorisio, M. S. (2008). „The Role of Vasoactive Intestinal Peptide (VIP) in Megakaryocyte Proliferation”.Journal of Molecular Neuroscience.37 (2): 160—167.PMID 18663606.doi:10.1007/s12031-008-9119-x.
^Freson, K.; Peeters, K.; De Vos, R.; Wittevrongel, C.; Thys, C.; Hoylaerts, M. F.; Vermylen, J.; Van Geet, C. (2007). „PACAP and its receptor VPAC1 regulate megakaryocyte maturation: Therapeutic implications”.Blood.111 (4): 1885—1893.PMID 18000164.doi:10.1182/blood-2007-06-098558.

Literatura

[уреди |уреди извор]

„Quaternary structure of rabbit skeletal muscle glycogen synthetase” [Quaternary structure of rabbit skeletal muscle glycogen synthetase].Doklady Akademii Nauk SSSR.222 (4): 997—1000. 1975.PMID 807467.
Sreedharan SP, Huang JX, Cheung MC, Goetzl EJ (1995).„Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene”.Proc. Natl. Acad. Sci. U.S.A.92 (7): 2939—43.PMC 42334 .PMID 7708752.doi:10.1073/pnas.92.7.2939.
Couvineau A; Gaudin P; Maoret JJ; et al. (1995). „Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP”.Biochem. Biophys. Res. Commun.206 (1): 246—52.PMID 7818527.doi:10.1006/bbrc.1995.1034. CS1 одржавање: Експлицитна употреба et al. (веза)
Gagnon AW, Aiyar N, Elshourbagy NA (1994).„Molecular cloning and functional characterization of a human liver vasoactive intestinal peptide receptor”.Cell. Signal.6 (3): 321—33.PMID 7917790.doi:10.1016/0898-6568(94)90037-X.
Sreedharan SP; Patel DR; Xia M; et al. (1994). „Human vasoactive intestinal peptide1 receptors expressed by stable transfectants couple to two distinct signaling pathways”.Biochem. Biophys. Res. Commun.203 (1): 141—8.PMID 8074647.doi:10.1006/bbrc.1994.2160. CS1 одржавање: Експлицитна употреба et al. (веза)
Couvineau A; Rouyer-Fessard C; Darmoul D; et al. (1994). „Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains”.Biochem. Biophys. Res. Commun.200 (2): 769—76.PMID 8179610.doi:10.1006/bbrc.1994.1517. CS1 одржавање: Експлицитна употреба et al. (веза)
Moody TW; Zia F; Draoui M; et al. (1993).„A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth”.Proc. Natl. Acad. Sci. U.S.A.90 (10): 4345—9.PMC 46507 .PMID 8389448.doi:10.1073/pnas.90.10.4345. CS1 одржавање: Експлицитна употреба et al. (веза)
Sreedharan SP, Patel DR, Huang JX, Goetzl EJ (1993). „Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor”.Biochem. Biophys. Res. Commun.193 (2): 546—53.PMID 8390245.doi:10.1006/bbrc.1993.1658.
Couvineau A; Fabre C; Gaudin P; et al. (1996). „Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane”.Biochemistry.35 (6): 1745—52.PMID 8639654.doi:10.1021/bi952022h. CS1 одржавање: Експлицитна употреба et al. (веза)
Pozo D, Guerrero JM, Segura JJ, Calvo JR (1997). „Thymosin alpha 1 interacts with the VIP receptor-effector system in rat and mouse immunocompetent cells”.Immunopharmacology.34 (2–3): 113—23.PMID 8886855.doi:10.1016/0162-3109(96)00131-2.
Couvineau A; Maoret JJ; Rouyer-Fessard C; et al. (1999). „Cloning and functional characterization of the human VIP1/PACAP receptor promoter”.Ann. N. Y. Acad. Sci.865: 59—63.PMID 9927997.doi:10.1111/j.1749-6632.1998.tb11163.x. CS1 одржавање: Експлицитна употреба et al. (веза)
Knudsen SM, Tams JW, Wulff BS, Fahrenkrug J (1999). „Importance of conserved cysteines in the extracellular loops of human PACAP/VIP1 receptor for ligand binding and stimulation of cAMP production”.Ann. N. Y. Acad. Sci.865: 259—65.PMID 9928020.doi:10.1111/j.1749-6632.1998.tb11186.x.
Marie J; Wakkach A; Coudray A; et al. (1999).„Functional expression of receptors for calcitonin gene-related peptide, calcitonin, and vasoactive intestinal peptide in the human thymus and thymomas from myasthenia gravis patients”.J. Immunol.162 (4): 2103—12.PMID 9973484. CS1 одржавање: Експлицитна употреба et al. (веза)
Mimuro H; Suzuki T; Suetsugu S; et al. (2000).„Profilin is required for sustaining efficient intra- and intercellular spreading of Shigella flexneri”.J. Biol. Chem.275 (37): 28893—901.PMID 10867004.doi:10.1074/jbc.M003882200. CS1 одржавање: Експлицитна употреба et al. (веза)
Nicole P; Maoret JJ; Couvineau A; et al. (2000). „Tryptophan 67 in the human VPAC(1) receptor: crucial role for VIP binding”.Biochem. Biophys. Res. Commun.276 (2): 654—9.PMID 11027527.doi:10.1006/bbrc.2000.3375. CS1 одржавање: Експлицитна употреба et al. (веза)
Bajo AM; Juarranz MG; Valenzuela P; et al. (2001). „Expression of vasoactive intestinal peptide (VIP) receptors in human uterus”.Peptides.21 (9): 1383—8.PMID 11072126.doi:10.1016/S0196-9781(00)00282-5. CS1 одржавање: Експлицитна употреба et al. (веза)
Lara-Marquez M; O'Dorisio M; O'Dorisio T; et al. (2001).„Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells”.J. Immunol.166 (4): 2522—30.PMID 11160313. CS1 одржавање: Експлицитна употреба et al. (веза)
Martin Shreeve S (2002). „Identification of G-proteins coupling to the vasoactive intestinal peptide receptor VPAC(1) using immunoaffinity chromatography: evidence for precoupling”.Biochem. Biophys. Res. Commun.290 (4): 1300—7.PMID 11812005.doi:10.1006/bbrc.2002.6342.
Dorsam G, Goetzl EJ (2002).„Vasoactive intestinal peptide receptor-1 (VPAC-1) is a novel gene target of the hemolymphopoietic transcription factor Ikaros”.J. Biol. Chem.277 (16): 13488—93.PMID 11812772.doi:10.1074/jbc.M107922200.
Branch DR; Valenta LJ; Yousefi S; et al. (2002). „VPAC1 is a cellular neuroendocrine receptor expressed on T cells that actively facilitates productive HIV-1 infection”.AIDS.16 (3): 309—19.PMID 11834941.doi:10.1097/00002030-200202150-00001. CS1 одржавање: Експлицитна употреба et al. (веза)

Vidi još

[уреди |уреди извор]

Receptor vazoaktivnog intestinalnog peptida

Transmembranski receptor:receptori spregnuti s G proteinom

Klasa A:Rodopsinu slični

Neurotransmiter

Adrenergički	α1 (A,B,D) • α2 (A,B,C) • β1 • β2 • β3
Purinski	Adenozinski (A1,A2A,A2B,A3) • P2Y (1,2,4,5,6,8,9,10,11,12,13,14)
Serotoninski	(svi osim 5-HT3)5-HT1 (A,B,D,E,F) • 5-HT2 (A,B,C) • 5-HT (4,5A,6,7)
Drugi	Acetilholin (M1,M2,M3,M4,M5) • Dopamin (D1,D2,D3,D4,D5) • Histamin (H1,H2,H3,H4) • Melatonin (1A,1B,1C) • TAAR (1,2,3,5,6,8,9)

Metaboliti i
signalni molekuli

Eikozanoidni	CysLT (1,2) • LTB4 (1,2) • FPRL1 • OXE • Prostaglandin (DP (1,2),EP (1,2,3,4),FP) • Prostaciklin • Tromboksan
Drugi	Žučna kiselina • Kanabinoidni (CB1,CB2,GPR (18,55,119)) • EBI2 • Estrogen • Slobodna masna kiselina (1,2,3,4) • Laktat • Lizofosfatidna kiselina (1,2,3,4,5,6) • Lizofosfolipid (1,2,3,4,5,6,7,8) • Niacin (1,2) • Oksoglutarat • PAF • Sfingozin-1-fosfat (1,2,3,4,5) • Sukcinat

Peptid

Neuropeptidni

B/W (1,2) • FF (1,2) • S • Y (1,2,4,5) • Neuromedin (B,U (1,2)) • Neurotenzin (1,2)

Drugi

Anafilatoksin (C3a,C5a) • Angiotenzin (1,2) • Apelin • Bombezin (BRS3,GRPR,NMBR) • Bradikinin (B1,B2) • Hemokin • Holecistokinin (A,B) • Endotelin (A,B) • Formil peptid (1,2,3) • FSH • Galanin (1,2,3) • GHB receptor • Gonadotropin-oslobađajući hormon (1,2) • Grelin • Kispeptin • Luteinizirajući hormon/horiogonadotropin • MAS (1,1L,D,E,F,G,X1,X2,X3,X4) • Melanokortin (1,2,3,4,5) • MCHR (1,2) • Motilin • Opioidni (δ,κ,μ,Nociceptin &ζ, ali neσ) • Oreksin (1,2) • Oksitocin • Prokineticin (1,2) • Prolaktin-oslobađajući peptid • Relaksin (1,2,3,4) • Somatostatin (1,2,3,4,5) • Tahikinin (1,2,3) • Tirotropin • Tirotropin-oslobađajući hormon • Urotenzin-II • Vazopresin (1A,1B,2)

Razno

Orfan	GPR (1,3,4,6,12,15,17,18,19,20,21,22,23,25,26,27,31,32,33,34,35,37,39,42,44,45,50,52,55,61,62,63,65,68,75,77,78,81,82,83,84,85,87,88,92,101,103,109A,109B,119,120,132,135,137B,139,141,142,146,148,149,150,151,152,153,160,161,162,171,173,174,176,177,182,183)
Drugi	Adrenomedulin • Mirisni • Opsin (3,4,5,1LW,1MW,1SW,RGR,RRH) • Proteazom-aktivirani (1,2,3,4) • SREB (1,2,3)

Klasa B:Sekretinu slični

Orfan	GPR (56,64,97,98,110,111,112,113,114,115,116,123,124,125,126,128,133,143,144,155,157)
Drugi	Moždano specifični angiogenezni inhibitor (1,2,3) • Kadherin (1,2,3) • Kalcitonin • CALCRL • CD97 • Kortikotropin-oslobađajući hormon (1,2) • EMR (1,2,3) • Glukagon (GR,GIPR,GLP1R,GLP2R) • Hormon rasta • PACAPR1 • GPR • Latrofilin (1,2,3,ELTD1) • Metuzalemski protein • Paratiroidni hormon (1,2) • Sekretin • Vazoaktivni intestinalni peptid (1,2)

Klasa C:Metabotropni
glutamat /feromon

Ukus	TAS1R (1,2,3) • TAS2R (1,3,4,5,8,9,10,12,13,14,16,19,20,30,31,38,39,40,41,42,43,45,46,50)
Drugi	Kalcijum-detektujući receptor • GABA B (1,2) • Glutamatni receptor (Metabotropni glutamat (1,2,3,4,5,6,7,8)) • GPRC6A • GPR (156,158,179) • RAIG (1,2,3,4) • VNR (1,2,3,5)

Klasa F:
Frizzled /Zaglađeni

Uvojiti	Frizzled (1,2,3,4,5,6,7,8,9,10)
Zaglađeni	Zaglađeni

Neuropeptidni receptori

Hormonski receptori

Hipotalamusni	CRH –FSH –LHRH –TRH –Somatostatin
Hipofizni	Vazopresin (1A,1B,2) –Oksitocin –LHCG –Tip I citokinski receptor (GH,Prolaktin) –TSH
Drugi	Atrijalni natriuretski faktor (NPR1,NPR2,NPR3) –Kalcitonin –Holecistokinin (A,B) –VIP

Opioidni receptori

Delta –Kapa –Mi –Sigma (1,2) –Nociceptin

Drugi neuropeptidni receptori

Angiotenzin –Bradikinin (B1,B2) /Tahikinin (TACR1) –Kalcitoninu sličan –Galanin –GPCR neuropeptid (B/W,FF,S,Y) –Neurotenzin

Преузето из „https://sr.wikipedia.org/w/index.php?title=VIPR1&oldid=30458609”

Категорије:

Сакривене категорије:

[8]ページ先頭